FY2025 · ended Jan 2, 2026 · Revenue $239.44M, -23.7% YoY · Filed Mar 3, 2026
STAAR Surgical Co (STAA) files with the SEC under industry code 3851, Ophthalmic Goods. In fiscal 2025, which ended Jan 2, 2026, it reported revenue of $239.4 million and a net loss of $80.4 million. Free cash flow was -$40.0 million. As of Oct 2, 2026 it held $206.4 million in cash and investments and $33.6 million in total debt.
Revenue (TTM)
$328.27M
+42.4% vs year-ago TTM
Net income (TTM)
$530,000
+100.5% vs year-ago TTM
Operating cash flow (TTM)
$21.40M
+172.1% vs year-ago TTM
Free cash flow (TTM)
$17.85M
+145.1% vs year-ago TTM
EPS (TTM)
$0.01
+100.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
49.51M
+0.4% vs prior year
Net cash
$172.77M
as of Oct 2, 2026
Operating margin
0.2%
FY 2026
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- STAA (Nasdaq)
- Fiscal year ends
- January 2
- Incorporated in
- DE
- Headquarters
- Monrovia, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 718937
- Former names
- STAAR SURGICAL COMPANY (until Aug 17, 2004)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- RxSight, Inc. RXST
- Innovative Eyewear Inc LUCY
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jan 2, 2026 |
FY 2024 Dec 27, 2024 |
FY 2023 Dec 29, 2023 |
FY 2022 Dec 30, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | $322.4M | $239.4M | $230.5M |
| Operating income | -$91.7M | -$12.6M | $28.1M | $43.8M | $33.3M |
| Net income | -$80.4M | -$20.2M | $21.3M | $39.7M | $27.5M |
| Diluted EPS | -$1.62 | -$0.41 | $0.43 | $0.80 | $0.56 |
| Operating cash flow | -$34.2M | $15.7M | $14.6M | $35.7M | $44.0M |
| Free cash flow | -$40.0M | -$7.7M | -$3.6M | $17.6M | $30.3M |
| Total assets | $451.7M | $509.5M | $488.7M | $418.8M | $345.8M |
| Total liabilities | $107.5M | $112.2M | $102.7M | $82.7M | $87.2M |
| Stockholders' equity | $344.2M | $397.3M | $386.0M | $336.1M | $261.6M |
| Cash and investments | $187.5M | $230.5M | $232.4M | $225.5M | $199.7M |
| Total debt | $38.4M | $38.7M | $35.8M | $31.0M | $32.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
All 1002 STAAR Surgical Co SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.